Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

2,700

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2020

Conditions
SchizophreniaMajor Depressive DisorderAnxiety Disorders
Interventions
DRUG

Risperidone

Risperidone tablet

DRUG

Olanzapine

Olanzapine tablet

DRUG

Aripiprazole

Aripiprazole tablet

Trial Locations (1)

300052

RECRUITING

Tianjin Medical University General Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Shanghai Mental Health Center

OTHER

collaborator

Nanjing Medical University

OTHER

collaborator

Tianjin Anding Hospital

OTHER

collaborator

Harbin First Specialist Hospital

UNKNOWN

collaborator

First Affiliated Hospital of Chongqing Medical University

OTHER

collaborator

Anhui Mental Health Center

UNKNOWN

collaborator

Wuhan Psychiatric Hospital

UNKNOWN

collaborator

Wenzhou Seventh People's Hospital

OTHER_GOV

collaborator

First Affiliated Hospital of Harbin Medical University

OTHER

lead

Tianjin Medical University General Hospital

OTHER